Duzhong Fang Attenuates the POMC-Derived Neuroinflammation in Parkinsonian Mice

References

• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–905. doi:10.1007/s00702-017-1686-y
   PubMed Web of Science ®Google Scholar
• Fabbri M, Reimão S, Carvalho M, et al. Substantia nigra neuromelanin as an imaging biomarker of disease progression in Parkinson’s disease. J Parkinsons Dis. 2017;7(3):491–501. doi:10.3233/JPD-171135
   PubMedGoogle Scholar
• Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46(Suppl 1):S30–S33. doi:10.1016/j.parkreldis.2017.07.033
   PubMed Web of Science ®Google Scholar
• Stojkovska I, Wagner BM, Morrison BE. Parkinson’s disease and enhanced inflammatory response. Exp Biol Med. 2015;240(11):1387–1395. doi:10.1177/1535370215576313
   PubMed Web of Science ®Google Scholar
• Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology. 2012;62(7):2154–2168. doi:10.1016/j.neuropharm.2012.01.028
   PubMed Web of Science ®Google Scholar
• Elzbieta J, Laura B, Carta AR, Phagocytosis M. Its regulation: a therapeutic target in Parkinson’s disease? Front Mol Neurosci. 2018;11:1–7. doi:10.3389/fnmol.2018.00144
   PubMed Web of Science ®Google Scholar
• Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell Death Differ. 2016;23(6):915–926. doi:10.1038/cdd.2015.172
   PubMed Web of Science ®Google Scholar
• Nau R, Ribes S, Djukic M, Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Front Cell Neurosci. 2014;8:138. doi:10.3389/fncel.2014.00138
   PubMed Web of Science ®Google Scholar
• Maatouk L, Compagnion AC, Sauvage MC, et al. TLR9 activation via microglial glucocorticoid receptors contributes to degeneration of midbrain dopamine neurons. Nat Commun. 2018;9(1):2450. doi:10.1038/s41467-018-04569-y
   PubMedGoogle Scholar
• Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev. 2011;11:CD008454. doi:10.1002/14651858
   Google Scholar
• Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson’s disease. Biochim Biophys Acta. 2009;1792(7):676–687. doi:10.1016/j.bbadis.2008.09.009
   PubMed Web of Science ®Google Scholar
• Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: a dose-response meta-analysis. Medicine. 2018;97(37):e12172. doi:10.1097/MD.0000000000012172
   PubMed Web of Science ®Google Scholar
• Poly TN, Islam MMR, Yang HC, Li YJ. Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: a meta-analysis. Eur J Clin Pharmacol. 2019;75(1):99–108. doi:10.1007/s00228-018-2561-y
   PubMed Web of Science ®Google Scholar
• Cayero-Otero MD, Espinosa-Oliva AM, Herrera AJ, et al. Potential use of nanomedicine for the anti-inflammatory treatment of neurodegenerative diseases. Curr Pharm Des. 2018;24(14):1589–1616. doi:10.2174/1381612824666180403113015
   PubMed Web of Science ®Google Scholar
• Mir RH, Shah AJ, Mohi-Ud-Din R, et al. Natural anti-inflammatory compounds as drug candidates in Alzheimer’s disease. Curr Med Chem. 2020;30. doi:10.2174/0929867327666200730213215
   Google Scholar
• Yao YY, Ling EA, Lu D. Microglia mediated neuroinflammation - signaling regulation and therapeutic considerations with special reference to some natural compounds. Histol Histopathol. 2020;35(11):1229–1250. doi:10.14670/HH-18-239
   PubMed Web of Science ®Google Scholar
• Wu HZ, Fang ZQ, Cheng PJ. The theory of Yin and Yang. U Chi L Rev. 2013;1:33–46. doi:10.1142/9781938134296_0003
   Google Scholar
• Fan S, Yin Q, Li D, et al. Anti-neuroinflammatory effects of Eucommia ulmoides Oliv. In a Parkinson’s mouse model through the regulation of p38/JNK-Fosl2 gene expression. J Ethnopharmacol. 2020;260:113016. doi:10.1016/j.jep.2020.113016
   PubMed Web of Science ®Google Scholar
• National Pharmacopoeia Commission. The Pharmacopoeia of the People’s Republic of China (Part I). Beijing: China Medical Science and Technology Press; 2020.
   Google Scholar
• García E, Villeda-Hernández J, Pedraza-Chaverrí J, Maldonado PD, Santamaría A. S-allylcysteine reduces the MPTP-induced striatal cell damage via inhibition of pro-inflammatory cytokine tumor necrosis factor-α and inducible nitric oxide synthase expressions in mice. Phytomedicine. 2010;18:65–73. doi:10.1016/j.phymed.2010.04.004
   PubMed Web of Science ®Google Scholar
• Huang D, Wang Z, Tong J, et al. Long-term changes in the nigrostriatal pathway in the MPTP mouse model of Parkinson’s disease. Neuroscience. 2018;369:303–313. doi:10.1016/j.neuroscience.2017.11.041
   PubMed Web of Science ®Google Scholar
• Wang CT, Mao CJ, Zhang XQ, et al. Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson’s disease. Mol Pain. 2017;13:1744806917691525. doi:10.1177/1744806917691525
   Web of Science ®Google Scholar
• Luo FC, Wang SD, Qi L, Song JY, Lv T, Bai J. Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. J Ethnopharmacol. 2011;133(2):448–453. doi:10.1016/j.jep.2010.10.017
   PubMed Web of Science ®Google Scholar
• Wang W, Shi L, Xie Y, et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease. Neurosci Res. 2004;48(2):195–202. doi:10.1016/j.neures.2003.10.012
   PubMed Web of Science ®Google Scholar
• Perez-Pardo P, Dodiya HB, Engen PA, et al. Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. Gut. 2019;68(5):829–843. doi:10.1136/gutjnl-2018-316844
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Cebrián C, Zucca FA, Mauri P, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633. doi:10.1038/ncomms4633
   PubMed Web of Science ®Google Scholar
• Yoon KW, Yang HS, Kim YM, et al. CIB1 protects against MPTP-induced neurotoxicity through inhibiting ASK1. Sci Rep. 2017;7(1):12178. doi:10.1038/s41598-017-12379-3
   PubMedGoogle Scholar
• Tritsch NX, Sabatini BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron. 2012;76(1):33–50. doi:10.1016/j.neuron.2012.09.023
   PubMed Web of Science ®Google Scholar
• Franceschelli S, Lanuti P, Ferrone A, et al. Modulation of apoptotic cell death and neuroprotective effects of glutathione-l-dopa codrug against H2O2-induced cellular toxicity. Antioxidants. 2019;8(8):319. doi:10.3390/antiox8080319
   Web of Science ®Google Scholar
• Butkovich LM, Houser MC, Tansey MG. α-synuclein and noradrenergic modulation of immune cells in Parkinson’s disease pathogenesis. Front Neurosci. 2018;12:626. doi:10.3389/fnins.2018.00626
   PubMed Web of Science ®Google Scholar
• Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132(Pt 2):288–295. doi:10.1093/brain/awn109
   PubMedGoogle Scholar
• Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003;106(6):518–526. doi:10.1007/s00401-003-0766-2
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–397. doi:10.1016/S1474-4422(09)70062-6
   PubMed Web of Science ®Google Scholar
• Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord. 2011;26(1):6–17. doi:10.1002/mds.23455
   PubMed Web of Science ®Google Scholar
• Herrero MT, Estrada C, Maatouk L, Vyas S. Inflammation in Parkinson’s disease: role of glucocorticoids. Front Neuroanat. 2015;9:32. doi:10.3389/fnana.2015.00032
   PubMed Web of Science ®Google Scholar
• Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39(1):151–170. doi:10.1016/0306-4522(90)90229-w
   PubMed Web of Science ®Google Scholar
• Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000;20(16):6309–6316. doi:10.1523/JNEUROSCI.20-16-06309.2000
   PubMed Web of Science ®Google Scholar
• Barcia C, Ros CM, Ros-Bernal F, et al. Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques. J Neuroimmunol. 2013;261(1–2):60–66. doi:10.1016/j.jneuroim.2013.05.001
   PubMed Web of Science ®Google Scholar
• Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi:10.1038/nature23672
   PubMed Web of Science ®Google Scholar
• Zhao X, Liao Y, Morgan S, et al. Noninflammatory changes of microglia are sufficient to cause epilepsy. Cell Rep. 2018;22(8):2080–2093. doi:10.1016/j.celrep.2018.02.004
   PubMed Web of Science ®Google Scholar
• Wu J, Ding DH, Li QQ, Wang XY, Sun YY, Li LJ. Lipoxin A4 regulates lipopolysaccharide-induced BV2 microglial activation and differentiation via the notch signaling pathway. Front Cell Neurosci. 2019;13:19. doi:10.3389/fncel.2019.00019
   PubMed Web of Science ®Google Scholar
• Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15(5):300–312. doi:10.1038/nrn3722
   PubMed Web of Science ®Google Scholar
• Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11–21. doi:10.1016/j.expneurol.2011.09.033
   PubMed Web of Science ®Google Scholar
• Michels M, Abatti MR, Ávila P, et al. Characterization and modulation of microglial phenotypes in an animal model of severe sepsis. J Cell Mol Med. 2020;24(1):88–97. doi:10.1111/jcmm.14606
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Nakaso K, Horikoshi Y, et al. System xc- in microglia is a novel therapeutic target for post-septic neurological and psychiatric illness. Sci Rep. 2019;9(1):7562. doi:10.1038/s41598-019-44006-8
   PubMedGoogle Scholar
• Lan X, Han X, Li Q, Yang QW, Wang J. Modulators of microglial activation and polarization after intracerebral haemorrhage. Nat Rev Neurol. 2017;13(7):420–433. doi:10.1038/nrneurol.2017.69
   PubMed Web of Science ®Google Scholar
• Hu X, Leak RK, Shi Y, et al. Microglial and macrophage polarization—new prospects for brain repair. Nat Rev Neurol. 2015;11(1):56–64. doi:10.1038/nrneurol.2014.207
   PubMed Web of Science ®Google Scholar
• Dai D, Yuan J, Wang Y, Xu J, Mao C, Xiao XY. Peli1 controls the survival of dopaminergic neurons through modulating microglia-mediated neuroinflammation. Sci Rep. 2019;9(1):8034. doi:10.1038/s41598-019-44573-w
   PubMedGoogle Scholar
• Brown GC. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans. 2007;35(Pt 5):1119–1121. doi:10.1042/BST0351119
   PubMedGoogle Scholar
• Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J. 2003;17(13):1954–1956. doi:10.1096/fj.03-0109fje
   PubMedGoogle Scholar
• Lecca D, Janda E, Mulas G, et al. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson’s disease models. Br J Pharmacol. 2018;175(16):3298–3314. doi:10.1111/bph.14214
   PubMed Web of Science ®Google Scholar
• Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57–69. doi:10.1038/nrn2038
   PubMed Web of Science ®Google Scholar
• Rojanathammanee L, Murphy EJ, Combs CK. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation. 2011;8:44. doi:10.1186/1742-2094-8-44
   PubMed Web of Science ®Google Scholar
• Nikolakopoulou AM, Dutta R, Chen Z, Miller RH, Trapp BD. Activated microglia enhance neurogenesis via trypsinogen secretion. Proc Natl Acad Sci U S A. 2013;110(21):8714–8719. doi:10.1073/pnas.1218856110
   PubMed Web of Science ®Google Scholar
• Truettner JS, Bramlett HM, Dietrich WD. Posttraumatic therapeutic hypothermia alters microglial and macrophage polarization toward a beneficial phenotype. J Cereb Blood Flow Metab. 2017;37(8):2952–2962. doi:10.1177/0271678X16680003
   PubMed Web of Science ®Google Scholar
• Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci. 2005;29(3):381–393. doi:10.1016/j.mcn.2005.03.005
   PubMed Web of Science ®Google Scholar
• Zhou X, Spittau B, Krieglstein K. TGFβ signalling plays an important role in IL4-induced alternative activation of microglia. J Neuroinflammation. 2012;9:210. doi:10.1186/1742-2094-9-210
   PubMed Web of Science ®Google Scholar
• Kroner A, Greenhalgh AD, Zarruk JG, et al. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron. 2014;83(5):1098–1116. doi:10.1016/j.neuron.2014.07.027
   PubMed Web of Science ®Google Scholar
• Benson MJ, Manzanero S, Borges K. Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models. Epilepsia. 2015;56(6):895–905. doi:10.1111/epi.12960
   PubMed Web of Science ®Google Scholar
• Zhang X, van den Pol AN. Hypothalamic arcuate nucleus tyrosine hydroxylase neurons play orexigenic role in energy homeostasis. Nat Neurosci. 2016;19(10):1341–1347. doi:10.1038/nn.4372
   PubMed Web of Science ®Google Scholar
• Nappi G, Petraglia F, Martignoni E, et al. Beta-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology. 1985;35(9):1371–1374. doi:10.1212/wnl.35.9.1371
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pro-opiomelanocortin (POMC) processing in Parkinson’s disease. Int J Neurosci. 1989;46(3–4):201–204. doi:10.3109/00207458908986258
   PubMed Web of Science ®Google Scholar
• Ropelle ER, Flores MB, Cintra DE, et al. IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKKβ and ER stress inhibition. PLoS Biol. 2010;8(8):e1000465. doi:10.1371/journal.pbio.1000465
   PubMed Web of Science ®Google Scholar
• Shi X, Wang X, Li Q, et al. Nuclear factor κB (NF-κB) suppresses food intake and energy expenditure in mice by directly activating the Pomcpromoter. Diabetologia. 2013;56(4):925–936. doi:10.1007/s00125-013-2831-2
   PubMed Web of Science ®Google Scholar
• Pereda MP, Lohrer P, Kovalovsky D, et al. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas. Exp Clin Endocrinol Diabetes. 2000;108(3):202–207. doi:10.1055/s-2000-7887
   PubMed Web of Science ®Google Scholar
• Sergeyev V, Broberger C, Hökfelt T. Effect of LPS administration on the expression of POMC, NPY, galanin, CART and MCH mRNAs in the rat hypothalamus. Brain Res Mol Brain Res. 2001;90(2):93–100. doi:10.1016/s0169-328x(01)00088-2
   PubMedGoogle Scholar
• Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468. doi:10.1152/ajpendo.00434.2002
   PubMed Web of Science ®Google Scholar
• Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. Thescientificworldjournal. 2014;10(1):1840. doi:10.1100/tsw.2010.173
   Google Scholar
• Wang M, Zhi D, Wang H, et al. TAT-HSA-α-MSH fusion protein with extended half-life inhibits tumor necrosis factor-α in brain inflammation of mice. Appl Microbiol Biotechnol. 2016;100(12):5353–5361. doi:10.1007/s00253-015-7251-4
   PubMed Web of Science ®Google Scholar
• Carniglia L, Ramírez D, Durand D, et al. Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases. Mediators Inflamm. 2017;2017:5048616. doi:10.1155/2017/5048616
   PubMed Web of Science ®Google Scholar